170 related articles for article (PubMed ID: 19204081)
1. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism.
Bains OS; Karkling MJ; Lubieniecka JM; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Mar; 332(3):755-63. PubMed ID: 20007405
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
4. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
6. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
8. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
[TBL] [Abstract][Full Text] [Related]
9. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase.
Skarka A; Skarydová L; Stambergová H; Wsól V
Chem Biol Interact; 2011 May; 191(1-3):66-74. PubMed ID: 21185270
[TBL] [Abstract][Full Text] [Related]
10. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Kassner N; Huse K; Martin HJ; Gödtel-Armbrust U; Metzger A; Meineke I; Brockmöller J; Klein K; Zanger UM; Maser E; Wojnowski L
Drug Metab Dispos; 2008 Oct; 36(10):2113-20. PubMed ID: 18635746
[TBL] [Abstract][Full Text] [Related]
11. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
12. A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.
Gonzalez-Covarrubias V; Ghosh D; Lakhman SS; Pendyala L; Blanco JG
Drug Metab Dispos; 2007 Jun; 35(6):973-80. PubMed ID: 17344335
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis.
El-Hawari Y; Favia AD; Pilka ES; Kisiela M; Oppermann U; Martin HJ; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):234-41. PubMed ID: 19061875
[TBL] [Abstract][Full Text] [Related]
14. Flavonoids as inhibitors of human carbonyl reductase 1.
Carlquist M; Frejd T; Gorwa-Grauslund MF
Chem Biol Interact; 2008 Jul; 174(2):98-108. PubMed ID: 18579125
[TBL] [Abstract][Full Text] [Related]
15. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
[TBL] [Abstract][Full Text] [Related]
16. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
17. Cellular pharmacology of amino acid derivatives of daunorubicin and doxorubicin in suspension of renal proximal tubules.
Hjelle JT; Baurain R; Masquelier M; Trouet A
J Pharmacol Exp Ther; 1984 May; 229(2):372-80. PubMed ID: 6585548
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
19. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells.
Gonzalez B; Akman S; Doroshow J; Rivera H; Kaplan WD; Forrest GL
Cancer Res; 1995 Oct; 55(20):4646-50. PubMed ID: 7553643
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
